Characterizing disease severity of COVID-19 is important to establish next steps for managing COVID-19 and mitigating disease progression in patients. View this CME/CE certified module outlining the evidence supporting treatment decision-making for COVID-19.
At the end of this CME/CE activity, participants should be able to apply the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild-to-moderate COVID-19.
The following learning objectives pertain only to those requesting CNE or CPE credit: Summarize the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild to moderate COVID-19.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chen reports that he is on the advisory board for Eli Lilly and Company.
Dr. Huhn reports that he receives grants and research support from Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare. He is on the advisory board for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare.
Dr. Savoy has no disclosures to report.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-142-H01-P.
Call us at 877.CME.PROS (877.263.7767).